Thromb Haemost. 2021 Aug;19(8):2002-2006. \[[PubMed: 33555096](https://pubmed.ncbi.nlm.nih.gov/33555096)\] 5. Weitz JI, Fredenburgh JC, Eikelboom JW. A Test in Context: D-Dimer. J Am Coll Cardiol. 2017 Nov 07;70(19):2411-2420. \[[PubMed: 29096812](https://pubmed.ncbi.nlm.nih.gov/29096812)\] 6. Ignjatovic V. Activated partial thromboplastin time. Methods Mol Biol. 2013;992:111-20. \[[PubMed: 23546708](https://pubmed.ncbi.nlm.nih.gov/23546708)\] 7. Chornenki NLJ, Fralick M, Sholzberg M. International normalized ratio and activated partial thromboplastin time testing. CMAJ. 2022 Aug 29;194(33):E1135. \[[PMC free article: PMC9435534](/pmc/articles/PMC9435534/)\] \[[PubMed: 36302103](https://pubmed.ncbi.nlm.nih.gov/36302103)\] 8. Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: an overview. Clin Chem Lab Med. 2017 May 01;55(6):800-805. \[[PubMed: 27754958](https://pubmed.ncbi.nlm.nih.gov/27754958)\] 9. Robert-Ebadi H, Righini M. D-dimer: Well beyond diagnosis! J Med Vasc. 2020 Sep;45(5):239-240. \[[PMC free article: PMC7343641](/pmc/articles/PMC7343641/)\] \[[PubMed: 32862979](https://pubmed.ncbi.nlm.nih.gov/32862979)\] 10. Sikes L, Charles K, Antigua A, Patel R, Imboywa S, Cherian P. Anti-Factor Xa Level Monitoring for Enoxaparin Prophylaxis and Treatment in High-Risk Patient Groups. HCA Healthc J Med. 2023;4(2):105-109. \[[PMC free article: PMC10324872](/pmc/articles/PMC10324872/)\] \[[PubMed: 37424985](https://pubmed.ncbi.nlm.nih.gov/37424985)\] **Disclosure:** Syed Rafay Zaidi declares no relevant financial relationships with ineligible companies. **Disclosure:** Preeti Rout declares no relevant financial relationships with ineligible companies.